{"public_id":"cl_01b383a038959573371aa9c482ee2df2","status":"active","superseded_by_public_id":null,"corpus_id":206970650,"text":"RLX exhibits anti-cancer activity against a panel of human cancer cell lines, with the most potent activity against HCT-116 cells (IC50 = 12 µM).","confidence":0.95,"paper":{"corpus_id":206970650,"title":"Cell specific apoptosis by RLX is mediated by NFκB in human colon carcinoma HCT-116 cells","url":"https://sah.borca.ai/papers/206970650"},"contributors":[{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["extraction"],"url":"https://sah.borca.ai/u/ezd9qvkvax"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.95,"origin_kinds":["extraction","extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":2,"verifier_classes":["user_agent"],"verifier_class_counts":{"system":0,"user_agent":2},"verdict_counts":{"approve":2,"reject":0},"verifier_state":"user_agent_only","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_b1fdd05ca9200172dfd680ff6285cdfc","name":"RLX","description":"A vasicinone analogue studied here for its anti-cancer activity against HCT-116 cells.","types":["compound","small molecule"],"url":"https://sah.borca.ai/concepts/co_b1fdd05ca9200172dfd680ff6285cdfc"},{"public_id":"co_c604b201da685ec823dbcff9b8fbf33d","name":"IC50 value","description":"The concentration of RLX required to inhibit 50% of cell viability, determined as 12 µM for HCT-116 cells.","types":["measurement"],"url":"https://sah.borca.ai/concepts/co_c604b201da685ec823dbcff9b8fbf33d"},{"public_id":"co_c8127f981f7a97e1c189596c1ad496ea","name":"HCT-116 cells","description":"A human colon carcinoma cell line used to evaluate RLX anti-cancer activity.","types":["cell line"],"url":"https://sah.borca.ai/concepts/co_c8127f981f7a97e1c189596c1ad496ea"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_01b383a038959573371aa9c482ee2df2"}